| Bioactivity | Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1]. | |||||||||
| Name | Ceritinib-d7 | |||||||||
| CAS | 1632484-77-5 | |||||||||
| Formula | C28H29D7ClN5O3S | |||||||||
| Molar Mass | 565.18 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl |
Ceritinib-d7
CAS: 1632484-77-5 F: C28H29D7ClN5O3S W: 565.18
Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.